CO2021005797A2 - Métodos y formulaciones para tratar náuseas y vómitos inducidos por quimioterapia - Google Patents

Métodos y formulaciones para tratar náuseas y vómitos inducidos por quimioterapia

Info

Publication number
CO2021005797A2
CO2021005797A2 CONC2021/0005797A CO2021005797A CO2021005797A2 CO 2021005797 A2 CO2021005797 A2 CO 2021005797A2 CO 2021005797 A CO2021005797 A CO 2021005797A CO 2021005797 A2 CO2021005797 A2 CO 2021005797A2
Authority
CO
Colombia
Prior art keywords
vomiting
chemotherapy
nausea
induced
formulations
Prior art date
Application number
CONC2021/0005797A
Other languages
English (en)
Inventor
Catherine Jacobson
Original Assignee
Tilray Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tilray Inc filed Critical Tilray Inc
Publication of CO2021005797A2 publication Critical patent/CO2021005797A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona una formulación de cannabidiol y delta-9-tetrahidrocannabinol. La formulación es una forma de dosificación oral sólida. En algunas realizaciones, la formulación es una formulación liposomal oral. La presente invención también proporciona métodos para tratar náuseas y vómitos inducidos por quimioterapia mediante la administración de tales formulaciones a un paciente antes y/o después de que el paciente reciba el tratamiento de quimioterapia. Las náuseas y los vómitos inducidos por quimioterapia que están tratándose pueden comprender náuseas y vómitos agudos inducidos por quimioterapia, náuseas y vómitos tardíos inducidos por quimioterapia o ambos.
CONC2021/0005797A 2018-10-10 2021-04-30 Métodos y formulaciones para tratar náuseas y vómitos inducidos por quimioterapia CO2021005797A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862743839P 2018-10-10 2018-10-10
PCT/US2019/055662 WO2020077103A1 (en) 2018-10-10 2019-10-10 Methods and formulations for treating chemotherapy-induced nausea and vomiting

Publications (1)

Publication Number Publication Date
CO2021005797A2 true CO2021005797A2 (es) 2021-05-20

Family

ID=68345091

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0005797A CO2021005797A2 (es) 2018-10-10 2021-04-30 Métodos y formulaciones para tratar náuseas y vómitos inducidos por quimioterapia

Country Status (12)

Country Link
US (1) US20200113847A1 (es)
EP (1) EP3863614A1 (es)
JP (1) JP2022502471A (es)
KR (1) KR20210116432A (es)
AU (1) AU2019357608A1 (es)
BR (1) BR112021006858A2 (es)
CA (1) CA3115985A1 (es)
CL (1) CL2021000882A1 (es)
CO (1) CO2021005797A2 (es)
MX (1) MX2021004138A (es)
PE (1) PE20211198A1 (es)
WO (1) WO2020077103A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3969054A4 (en) * 2019-05-16 2023-09-06 Aegis Therapeutics, LLC COMPOSITIONS CONTAINING OIL-SOLUBLE DRUGS AND METHODS OF USING SUCH COMPOSITIONS

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
US20040248970A1 (en) * 2003-04-10 2004-12-09 Webster G.R. Barrie CBD-delta8-THC composition
WO2005053612A2 (en) * 2003-11-26 2005-06-16 Shire Laboratories, Inc. Micellar systems useful for delivery of lipophilic or hydrophobic compounds
CA2608399A1 (en) * 2005-05-13 2006-11-23 Unimed Pharmaceuticals, Inc. Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
AU2014347807A1 (en) * 2013-10-31 2016-05-26 Full Spectrum Laboratories, Ltd. Terpene and cannabinoid formulations
EP3463304A4 (en) * 2016-05-24 2020-01-08 Bol Pharma Ltd. COMPOSITIONS COMPRISING CANNABIDIOL AND HYALURONIC ACID FOR THE TREATMENT OF INFLAMMATORY JOINT DISEASES
CA3036585A1 (en) * 2016-09-27 2018-04-05 CannTab Therapeutics Limited Sustained release cannabinoid formulations
WO2018071581A1 (en) * 2016-10-12 2018-04-19 Columbia Care, Llc An oral composition of extracted cannabinoids and methods of use thereof
AU2018206564B2 (en) * 2017-01-03 2023-12-07 Spoke Sciences, Inc. Medicinal compounds and nutritional supplements
MX2019009642A (es) * 2017-02-15 2019-11-11 Molecular Infusions Llc Formulaciones.
US10307392B2 (en) * 2017-10-21 2019-06-04 Alexander Kariman Compound and method for treatment of diseases and disorders
WO2019100007A1 (en) * 2017-11-17 2019-05-23 Tilray, Inc. Cannabinoid compositions
EP3755372A1 (en) * 2018-02-23 2020-12-30 Nicola Michael Spirtos Cannabis based therapeutic and method of use
EP3829554A4 (en) * 2018-07-31 2022-04-20 Auscann Group Holdings Ltd PHARMACEUTICAL COMPOSITIONS "SELF-EMULSIFYING SOLIDS

Also Published As

Publication number Publication date
BR112021006858A2 (pt) 2021-07-13
EP3863614A1 (en) 2021-08-18
AU2019357608A1 (en) 2021-05-27
CA3115985A1 (en) 2020-04-16
KR20210116432A (ko) 2021-09-27
WO2020077103A1 (en) 2020-04-16
PE20211198A1 (es) 2021-07-01
CL2021000882A1 (es) 2021-08-27
MX2021004138A (es) 2021-08-05
US20200113847A1 (en) 2020-04-16
JP2022502471A (ja) 2022-01-11

Similar Documents

Publication Publication Date Title
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
NI201700137A (es) Derivados de indol mono o disustituidos como inhibidores de la replicaciã“n viral del dengue
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19070369A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
NI201900098A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
CL2019003572A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
CL2020002465A1 (es) Método de tratamiento de enfermedad fibrótica
CL2019003533A1 (es) Uso de vibegron para tratar vejiga sobreactiva.
CO2019007879A2 (es) Formas cristalinas de tebipenem pivoxil, composiciones que incluyen a las mismas, métodos de fabricación, y métodos de utilización
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
CL2022001458A1 (es) Método para el tratamiento de cáncer utilizando célula ad-yuvante artificial (aavc)
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
CO2021005797A2 (es) Métodos y formulaciones para tratar náuseas y vómitos inducidos por quimioterapia
CL2021001635A1 (es) Tratamiento combinado para tumores sólidos con docetaxel y un inhibidor de cyp3a
AR102308A1 (es) Composición farmacéutica para usar en el tratamiento o prevención de deficiencias de vitaminas y minerales en pacientes sometidos a cirugía de bypass gástrico
AR101901A1 (es) Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod
ECSP19000167A (es) Métodos y composiciones para el tratamiento de la hipercalciuria y la nefrolitiasis
AR108792A1 (es) Composiciones que comprenden timolol